Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amgen (AMGN) Sees Double-Digit EPS Growth Out to 2018; UBS Raises Price target to $180
October 29, 2015 10:46 AM EDTUBS reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target to $180.00 (from $168.00), following the company's 3Q earnings results. AMGN reported a $0.34 EPS beat on another strong quarter of key product growth and cost controls. Management still sees double-digit EPS growth out to 2018.
Analyst Matthew Roden commented, "AMGN reported a $0.34 EPS beat (14% over consensus) on another strong quarter of... More
Roth Capital Maintains Cytokinetics (CYTJK) at 'Buy' Amid Encouraging COSMIC-HF Data
October 27, 2015 2:52 PM EDTRoth Capital affirms Cytokinetics (Nasdaq: CYTK) with a Buy rating and $18 price target after the company and Amgen (Nasdaq: AMGN)... More
Amgen (AMGN), Cytokinetics (CYTK) Announce Statistically Significant Data from COSMIC-HF Expansion Study
October 27, 2015 8:01 AM EDTAmgen (NASDAQ: AMGN) and Cytokinetics Incorporated (Nasdaq: CYTK) announced that data from the expansion phase of COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, showed statistically significant improvements in several measures of cardiac function, including systolic ejection time, stroke volume and N-terminal-pro-brain natriuretic peptide, at 20 weeks following randomization. The pharmacodynamic effects of omecamtiv mecarbil were generally dose dependent. Omecamtiv mecarbil, a novel investigational cardiac myosin activator, enhances cardiac... More
